

Department of Radiation Oncology

Monthly Research Update: October 2022

ASTRO, RSNA Funding for Research, Education

OCTOBER AT A GLANCE TOTALS

Clinical trials

Total enrolled	42
GCC, other	15
NRG, NCI, co-ops	1
PCG Registry	26

Grants and contracts

New awards	0
Submitted	1

Articles published	8
--------------------	---

Securing extramural support for research projects is challenging for junior faculty, residents, and postdoctoral fellows, in part because federal funding initiatives favor applicants with significant preliminary data and/or existing research collaborations. One potential solution lies in the wide range of grants and fellowships offered by professional societies. The American Society for Radiation Oncology (ASTRO), for example, sponsors several types of [research funding](#) for faculty and residents, including seed grants for both clinical and physics residents, as well as fellowship opportunities with industry partners. ASTRO's Radiation Oncology Institute issues a separate [yearly RFP](#) for proposals up to \$100,000 to address specified technology/methodology topics. ASTRO also offers support for educational projects and professional development. The Radiological Society of North America sponsors a number of [educational, research, and professional development grants](#) for residents and junior faculty, in addition to recognition awards for senior researchers.

Almost every major professional society offers research and educational support of some type. Some programs, like those of the [American Cancer Society](#), are well known, with strong competition among applicants. In general, however, pools of applicants for professional society awards are smaller and application processes are simpler in comparison to those for federal funding. A search of professional societies in your areas of interest is likely to yield new resources and ideas for research directions. Another reliable site is our UMSOM Center for Advance Research and Training Innovation, where the [Resources](#) page offers a diverse and updated range of funding mechanisms and helpful suggestions.

Information for this monthly update should be provided no later than the second Wednesday of each month to Miek Segers at msegers@som.umaryland.edu. The update will be published on the second Friday of each month.

Have questions about identifying a funding source? Finding research partners across the UMB/UM campuses or at another university? Defining future research strategies? Or organizing your thoughts on (virtual) paper? Contact Nancy Knight, PhD, Director of Academic and Professional Development for the department, at nknight@umm.edu

Clinical Trial Enrollment

- 26 patients were enrolled at MPTC on the **PCG Registry**
- 3 patients were enrolled at MPTC on the **Deep Thermal Therapy HUD**
- 6 patients were enrolled at MPTC on **GCC 19146**: Comparison and verification of radiation planning for pencil beam scanning proton therapy using single energy and dual energy computed tomography simulation methods
- 1 patient was enrolled at MPTC on **GCC 19140**: Pilot study of laser interstitial thermal therapy followed by hypofractionated radiation therapy for recurrent high-grade gliomas
- 1 patient was enrolled at UMMC on **GCC 1944**: A randomized phase III trial of two standard dose fractionation regimens for adjuvant vaginal brachytherapy in early-stage endometrial cancer
- 1 patient was enrolled at UMMC on **GCC 1940**: A prospective comparative study of outcomes with proton and photon radiation in prostate cancer (**COMPARE**)
- 1 patient was enrolled at UCH on **RTOG 1216**: Randomized phase II/III trial of adjuvant radiation therapy with cisplatin, docetaxel-cetuximab, or cisplatin-atezolizumab in pathologic high-risk squamous cell cancer of the head and neck
- 1 patient was enrolled at BWMC on **GCC 15100**: Pragmatic phase III randomized trial of proton vs. photon therapy for patients with non-metastatic breast cancer: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium trial
- 1 patient was enrolled at CMRO and 1 at MPTC on **GCC 21136**: Phase 2 randomized total eradication of metastatic lesions following definitive radiation to the prostate in de novo oligometastatic prostate cancer (TERPS) trial

Grants and Contracts

Submitted:

- **Lei Ren, PhD, PD/PI**, PAR-22-123 Bioengineering Partnerships with Industry (U01 Clinical Trial Optional), NIH grant collaboration with University of California, Irvine, for “3D in vivo dosimetry for FLASH proton therapy” (08/2023-07/2028; \$1,007,967).

Articles Published

Entered into PubMed October 13–November 9. Titles link to PubMed abstracts, with full-text links.

1. **Biswal NC, Rodrigues DB, Yao W, Molitoris JK, Witek ME, Chen S.** Evaluation of intrafraction couch shifts for proton treatment delivery in head-and-neck cancer patients: Toward optimal imaging frequency. *J Appl Clin Med Phys.* 2022 Oct 14:e13795. Online ahead of print.
2. Glicksman RM, Palma DA, Deek MP, Tsai CJ, Chmura S, Siva S, Ost P, **Tran PT**, Berlin A. Stereotactic body radiation therapy for oligometastasis: GUst do it? *Int J Radiat Oncol Biol Phys.* 2022 Nov 15;114(4):561-570.
3. Huynh MA, Tang C, Siva S, Berlin A, Hannan R, Warner A, Koontz B, De Meeleer G, Palma D, Ost P, **Tran PT.** Review of prospective trials assessing the role of stereotactic body radiation therapy for metastasis-directed treatment in oligometastatic genitourinary cancers. *Eur Urol Oncol.* 2022 Oct 22:S2588-9311(22)00171-7. Online ahead of print.
4. Kerans SJ, Samanta S, **Vyfhuis MAL, Guerrero M, Bang CK, Mishra MV, Rana Z, Amin PP, Kwok Y, Naslund MJ, Molitoris JK.** Racial analysis of clinical & biochemical outcomes in prostate cancer patients treated with low-dose-rate brachytherapy. *Int J Radiat Oncol Biol Phys.* 2022 Nov 3:S0360-3016(22)03474-5. Online ahead of print.
5. Lee EE, Singh T, Hu C, Han M, Deville CJ, Halthore A, Greco S, **Tran P**, DeWeese T, Song DY. The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy. *Prostate.* 2022 Oct 31. Online ahead of print.
6. Patel CG, Peterson J, Aznar M, Tseng YD, Lester S, Pafundi D, Flampouri S, **Mohindra P**, Parikh RR, Mailhot Vega R, Konig L, Plastaras JP, Bates JE, Loap P, Kirova YM, Orlandi E, Lütgendorf-Caucig C, Ntentas G, Hoppe B. Systematic review for deep inspiration breath hold in proton therapy for mediastinal lymphoma: A **PTCOG Lymphoma Subcommittee report and recommendations.** *Radiother Oncol.* 2022 Oct 14;177:21–32. Online ahead of print.
7. Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, **Tran PT**, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY. The 5-hydroxymethylcytosine landscape of prostate cancer. *Cancer Res.* 2022 Nov 2;82(21):3888–3902.
8. **Tran PT**, Sutera P, Phillips RM, Deek MP, Chmura S. From idea to clinical practice: A brief history of oligometastatic disease. *Int J Radiat Oncol Biol Phys.* 2022 Nov 15;114(4):576–580.

Important Dates for Upcoming Funding Submissions

Below is an updated calendar with firm due dates for upcoming major NIH deadlines (individual RFA/PA dates may differ). Contact the Department Office of Research Administration (DORA) (msegers@som.umaryland.edu) ASAP if you plan to submit any funding proposal, regardless of funder. Failure to meet these deadlines may result in delaying your submission until the next cycle (if available).

NIH deadline	DORA budget, prelim materials	Dean/SOM prelim materials	FINAL Dean/SOM/SPA
R01 new sub. 02/06/23	01/23/23	01/26/23	01/30/23
R21 new sub. 02/16/23	02/02/23	02/06/23	02/09/23
R01 Resub. 03/05/23	02/21/23	02/23/23	02/27/23
R21 Resub. 03/16/23	03/03/23	03/07/23	03/09/23

Also attached to this issue of the MRU, please see the FY23 NIH deadlines as provided by the UMSOM Dean’s Office.

2023 NIH Standard Due Dates and Internal Routing Deadlines

Updated 11/01/2022

Activity Code	Cycle I			Cycle II			Cycle III		
	NIH deadline	ORA deadline	SPA deadline	NIH deadline	ORA deadline	SPA deadline	NIH deadline	ORA deadline	SPA deadline
AIDS related (<i>all</i>)	<u>May 7th</u>	April 27th	May 1st	Sept 7th	Aug 28th	Aug 30th	<u>Jan 7th, 2024</u>	Jan 2nd *	Jan 2nd *
P series (<i>all</i>)	Jan 25th	Jan 13th	Jan 18th	May 25th	May 16th	May 18th	Sept 25th	Sept 14th	Sept 18th
R18, U18, R25 (<i>all</i>)	Jan 25th	Jan 13th	Jan 18th	May 25th	May 16th	May 18th	Sept 25th	Sept 14th	Sept 18th
Construction grants (<i>all</i>)	Jan 25th	Jan 13th	Jan 18th	May 25th	May 16th	May 18th	Sept 25th	Sept 14th	Sept 18th
T series, D series (<i>all</i>)	Jan 25th	Jan 13th	Jan 18th	May 25th	May 16th	May 18th	Sept 25th	Sept 14th	Sept 18th
R01 & U01 (<i>new</i>)	<u>Feb 5th</u>	Jan 26th	Jan 30th	June 5th	May 25th	May 30th * #	Oct 5th	Sept 26th	Sept 28th
K series (<i>new</i>)	<u>Feb 12th</u>	Feb 2nd	Feb 6th	June 12th	June 1st	June 5th	Oct 12th	Oct 3rd	Oct 5th
R03, R21, R33, R21/R33, R34, R36, U34, UH2, UH3, UH2/UH3 (<i>new</i>)	Feb 16th	Feb 7th	Feb 9th	June 16th	June 7th	June 9th	Oct 16th	Oct 5th	Oct 9th
R01 and U01 (<i>renewal, resubmission, revision</i>)	<u>March 5th</u>	Feb 23th	Feb 27th	July 5th	June 23rd	June 27th	<u>Nov 5th</u>	Oct 26th	Oct 30th
K series (<i>renewal, resubmission, revision</i>)	<u>March 12th</u>	March 2nd	March 6th	July 12th	June 30th	July 5th	<u>Nov 12th</u>	Nov 2nd	Nov 6th
R03, R21, R33, R21/R33, R34, R36, U34, UH2, UH3, UH2/UH3 (<i>renewal, resubmission, revision</i>)	March 16th	March 7th	March 9th	<u>July 16th</u>	July 6th	July 10th	Nov 16th	Nov 7th	Nov 9th
F series (<i>all</i>)	<u>Apr 8th</u>	March 30th	Apr 3rd	Aug 8th	July 28th	Aug 1st	Dec 8th	Nov 29th	Dec 1st
R13 & U13 (<i>all</i>)	Apr 12th	Apr 3rd	Apr 5th	<u>Aug 12th</u>	Aug 3rd	Aug 7th	Dec 12th	Dec 1st	Dec 5th

NIH deadlines in **bold underline** fall on a weekend or federal holiday and will be shifted to the next business day, per NIH policy. Internal deadlines are calculated according to the shifted NIH deadline.

ORA Deadline: Personnel, effort, budget materials, performance site and compliance forms routed in **final form, 7 business days** prior to NIH deadline.

SPA Deadline: All proposal materials routed in **final form** by 5 pm, **5 business days** prior to NIH deadline.

* Extended internal deadlines due to a campus holiday. # Following Memorial Day, final proposals must be at SPA by 9:00 am on May 30th.